Terns Pharmaceuticals, Inc.
Terns Pharmaceuticals, Inc. (TERN) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · TERN · as of Jun 8, 2026
Activity summary
Buy transactions
0
P-Purchase only
Sell transactions
14
12 Months
Buy/Sell ratio
0.00
Buy/Sell (by trades)
Overall sentiment
Terns Pharmaceuticals, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 8, 2026
TERN insider buying and selling by quarter
TERN insider selling · TERN insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 8, 2026
Active insiders
Most active in past 12 months · TERN ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
TERN executive sell shares · TERN board member insider trading · TERN insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| May 5, 2026 | Kuriakose Emil Chief Medical Officer | Other | 24,562 | $1.30M⚡ | Form 4 |
| May 5, 2026 | Kuriakose Emil Chief Medical Officer | Other | 81,953 | $4.34M⚡ | Form 4 |
| May 5, 2026 | Gengos Andrew CFO | Other | 40,503 | $2.15M⚡ | Form 4 |
| May 5, 2026 | Gengos Andrew CFO | Other | 68,750 | $3.64M⚡ | Form 4 |
| May 5, 2026 | Burroughs Amy L. CEO · Director | Other | 8,319 | $441K | Form 4 |
| May 5, 2026 | Burroughs Amy L. CEO · Director | Other | 150,000 | $7.95M⚡ | Form 4 |
| Apr 1, 2026 | Kuriakose Emil Chief Medical Officer | Sale | 942 | $50K | Form 4 |
| Mar 16, 2026 | Burroughs Amy L. CEO · Director | Option | 14,583 | $68K | Form 4 |
| Mar 16, 2026 | Burroughs Amy L. CEO · Director | Sale | 11,813 | $550K | Form 4 |
| Mar 16, 2026 | Burroughs Amy L. CEO · Director | Sale | 2,770 | $131K | Form 4 |
| Feb 17, 2026 | Burroughs Amy L. CEO · Director | Option | 14,583 | $68K | Form 4 |
| Feb 17, 2026 | Burroughs Amy L. CEO · Director | Sale | 2,341 | $89K | Form 4 |
| Feb 17, 2026 | Burroughs Amy L. CEO · Director | Sale | 8,159 | $320K | Form 4 |
| Feb 17, 2026 | Burroughs Amy L. CEO · Director | Sale | 4,083 | $163K | Form 4 |
| Jan 14, 2026 | Kuriakose Emil Chief Medical Officer | Award | 56,250 | — | Form 4 |
| Jan 14, 2026 | Gengos Andrew CFO | Award | 68,750 | — | Form 4 |
| Jan 15, 2026 | Burroughs Amy L. CEO · Director | Option | 14,583 | $68K | Form 4 |
| Jan 15, 2026 | Burroughs Amy L. CEO · Director | Option | 27,083 | $126K | Form 4 |
| Jan 15, 2026 | Burroughs Amy L. CEO · Director | Option | 27,083 | $126K | Form 4 |
| Jan 15, 2026 | Burroughs Amy L. CEO · Director | Sale | 61,228 | $2.27M⚡ | Form 4 |
| Jan 15, 2026 | Burroughs Amy L. CEO · Director | Sale | 7,521 | $282K | Form 4 |
| Jan 14, 2026 | Burroughs Amy L. CEO · Director | Award | 150,000 | — | Form 4 |
| Jan 5, 2026 | Burroughs Amy L. CEO · Director | Option | 150,000 | — | Form 4 |
| Jan 5, 2026 | Burroughs Amy L. CEO · Director | Sale | 71,339 | $2.72M⚡ | Form 4 |
| Jan 2, 2026 | Burroughs Amy L. CEO · Director | Option | 21,551 | $100K | Form 4 |
Kuriakose Emil
Chief Medical Officer
Date
May 5
Shares
24,562
Price
$53.00
Value
$1.30M ⚡
Kuriakose Emil
Chief Medical Officer
Date
May 5
Shares
81,953
Price
$53.00
Value
$4.34M ⚡
Burroughs Amy L.
CEO · Director
Date
May 5
Shares
150,000
Price
$53.00
Value
$7.95M ⚡
Burroughs Amy L.
CEO · Director
Date
Jan 15
Shares
27,083
Price
$4.64
Value
$126K
Burroughs Amy L.
CEO · Director
Date
Jan 15
Shares
27,083
Price
$4.64
Value
$126K
Burroughs Amy L.
CEO · Director
Date
Jan 15
Shares
61,228
Price
$37.02
Value
$2.27M ⚡
Burroughs Amy L.
CEO · Director
Date
Jan 5
Shares
71,339
Price
$38.10
Value
$2.72M ⚡
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About TERN insider trading
TERN insider trades
Terns Pharmaceuticals, Inc. (TERN) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Burroughs Amy L. (CEO · Director), Kuriakose Emil (Chief Medical Officer), Gengos Andrew (CFO). Over the past 12 months, 4 insiders have filed transactions with the SEC. TERN insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Terns Pharmaceuticals, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
TERN insider trading · 5 questionsThe insiders of Terns Pharmaceuticals, Inc. (TERN) include executives and directors such as Burroughs Amy L. (CEO · Director), Kuriakose Emil (Chief Medical Officer), Gengos Andrew (CFO), among others. Over the past 12 months, 4 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026